A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Brandes, Alba A
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. [electronic resource] - Neuro-oncology 08 2016 - 1146-56 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1523-5866
10.1093/neuonc/now009 doi
Antineoplastic Agents, Alkylating--adverse effects
Brain Neoplasms--drug therapy
Disease-Free Survival
Drug Therapy, Combination--adverse effects
Female
Glioblastoma--drug therapy
Humans
Kaplan-Meier Estimate
Lomustine--adverse effects
Male
Middle Aged
Pyrazoles--adverse effects
Quinolines--adverse effects
Treatment Outcome
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma. [electronic resource] - Neuro-oncology 08 2016 - 1146-56 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1523-5866
10.1093/neuonc/now009 doi
Antineoplastic Agents, Alkylating--adverse effects
Brain Neoplasms--drug therapy
Disease-Free Survival
Drug Therapy, Combination--adverse effects
Female
Glioblastoma--drug therapy
Humans
Kaplan-Meier Estimate
Lomustine--adverse effects
Male
Middle Aged
Pyrazoles--adverse effects
Quinolines--adverse effects
Treatment Outcome